
Sleep Like—Hatch Cofounders Ann Crady Weiss And Dave Weiss
Sleep Like is a column in which Forbes Vetted asks entrepreneurs and tastemakers to reveal the go-to sleep essentials that help them rest, recharge and ultimately conquer their busy days.
Since the start of their company in 2014, Hatch cofounders Ann Crady Weiss and Dave Weiss have been in the business of sleep solutions. When their third child struggled to sleep, they launched Hatch Rest, a kid-friendly sound machine, night-light and sleep trainer to curb the nightly army crawl out of his room. Later, when Dave's chronic insomnia and Ann's work-related stress spiked along with the growth of the brand, they were inspired to create a solve for adults: the Hatch Restore, a sunrise alarm clock meets sound machine that encourages deep rest and gentle rises.
The brand's smart tech devices helped the Weiss family—and countless others—set and stick to a sleep routine that's based in behavioral science. But still, like many married couples, Ann and Dave found that other interruptions (differing sleep styles, nightly tossing and turning) often led one of them to head from the bed to the couch in the hopes of snagging that coveted slumber. Eventually, they decided the benefits of sleeping in the same bed couldn't compete with the quality rest they got while sleeping apart. So the official solution, in this case, was to separate their sleeping arrangements altogether, a decision more colloquially known as a sleep divorce.
According to the American Academy of Sleep Medicine (AASM), many U.S. couples have gone down a similar path. A 2023 AASM survey found that more than one-third of people occasionally or consistently sleep in another room to accommodate a partner. For Ann and Dave, it has been a mutually beneficial way to prioritize their well-being. 'It's still important for us to be able to connect as a couple, so every night, we spend time together in our main bedroom, which is actually mine,' says Ann, who also wrote an essay on the topic for Hatch's blog last year. 'And then, we go our separate ways when it's time to sleep. It's wonderful, and I actually sleep so much better now.'
For Dave, sleeping separately has helped with his insomnia, too. 'We've always gone to bed at different times—I'm usually the last to fall asleep, so now Ann can go earlier in the evening without any disruption,' he says. Although they sleep apart, the couple does share a love for the same rotation of quality sleep products, including plush down pillows from Quince, crisp cotton sheets by Brooklinen and, of course, a custom wind-down routine with their Hatch Restore. Says Dave: 'Above all, we enjoy creating a sleep environment that works for us.'
Read on to shop Ann and Dave's go-to picks for achieving deep, restful sleep—together or apart.
Nico Zurcher
'My Hatch Restore is the number one sleep essential I can't live without,' says Ann of the sunrise alarm clock and sound machine that's available in four colors, including a new rosy hue (right). 'Right now, I'm loving the sound baths and irreverent meditations, and I transition to a rain sound during the night. Then, around 6:30 a.m., my room starts to fill with the light, and I wake up to the voice of drag queen Jaida Essence Hall telling me, 'Girl, get out of bed. You're going to slay the day.''
Quince
'I'm constantly searching for the ultimate pillow,' Dave says. 'I've had three back surgeries, and I'm also a 6-foot-7 side sleeper, so it's hard to get comfortable, period. Right now, Ann and I are both using this Quince down pillow. I use one to support my neck and another to support my free shoulder.' Adds Ann: 'I'm a side and back sleeper, and I love that it works for both. It's a nice, comfy option.'
Brooklinen
'The Classic Percale sheets from Brooklinen are great,' Ann says. 'I have the window pane print, and Dave has the solid white color. I love that they have long and short label tags inside, so when you're putting on the fitted sheet, it's easy to do. It's such a small detail but completely game-changing.'
The Company Store
'We both use the same cozy down comforter from The Company Store. I have allergies, so I also use a hypoallergenic cover from Amazon for my comforter and pillow,' Ann says.
Leesa
'We're currently using Leesa mattresses,' Dave says. 'Now that we're out of the traditional spring mattress era, there are so many high-quality options to choose from. It's really hard to notice the difference because they're all so much better.'
Target
'Ricola's lemon-flavored, sugar-free cough drops are an essential for me,' Ann says. 'I have allergies, so sometimes I get stuffed up. When I eat one of these, even in the middle of the night, I don't get a dry mouth, and I feel so much better.'
Lunya
'Dave is not a pajama guy, and sometimes I just sleep in a T-shirt and undies,' Ann says. 'But I do have a pair of Lunya pajamas that I really like. This set includes a short-sleeve tee and shorts that are lightweight and breathable.'
Amazon
'When I need to unwind at night, I use my Hatch Restore for meditations, or I pick up a good book. Right now, I'm reading the novel Hello Beautiful, which is incredible,' Ann says. Dave's relaxation routine involves some gaming. 'I like to play chess online,' he says. 'It was initially a pandemic hobby, but I noticed that it requires enough of my attention that the things that were on my mind kind of melt away when I play. When I return, I feel just a little more refreshed.'
Amazon
'Next to my bed, I always keep some Blistex lip balm to make sure my lips aren't too dry,' Ann says. 'Blistex is not a very sexy brand, but that's what I use—and it totally works.'
Hatch
'Eight years after our second child was born, we had our 'bonus baby,' and he struggled with bedtime, so Hatch was created out of a necessity to help people train their kids to sleep through sound and light,' Ann says. 'The Hatch Rest can really help you establish a good routine. I also recommend that any new parents get educated about sleep for babies, whether that's through a sleep coach or books on the topic. A great swaddle also helps. We've bought the Ollie Swaddle a bunch of times.'
Papier
'As a parent, it's important to have a journal to record your own experiences,' Ann says. 'You're so exhausted, and time flies, but whether I'm feeling high or low, I like to write things down so I can remember to keep things in perspective.'

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Eater
2 days ago
- Eater
Seattle's Vietnamese Coffee Boom Is Spreading to Wallingford
Coffeeholic House is absolutely addicted to opening new cafes. The local chain, which calls itself Seattle's first Vietnamese coffee shop, opened in March 2020 — the onset of the COVID pandemic — and became wildly popular on TikTok thanks to its colorful, photogenic drinks that are often topped with cold foam or cheese foam. Coffeeholic started in Columbia City but now has locations in Greenwood and Bellevue — and soon Wallingford, according to the Puget Sound Business Journal . The Journal reports that the new location, which will open sometime this summer, is at the bottom of the Chronicle apartment building on Wallingford Avenue near North 45th Street. It'll serve drinks like the ube-centric Purple Haze and the Tiramisu Egg Coffee, which comes garnished with a ladyfinger cookie. Those sorts of eye-catching, tastebud-tingling drinks are pretty common in Seattle thanks to the Vietnamese coffee boom that was launched in part by Coffeeholic. A stylish new Vietnamese cafe called Phe just opened on Capitol Hill; Aroom, a popular cafe in Fremont, is eyeing an expansion itself. You can also find fine examples of phin-brewed coffee concoctions at places like Pioneer Square sandwich shop Saigon Drip Cafe, or the swanky waterfront Bellevue restaurant Anchovies and Salt, or MCozy, a University Village–adjacent brunch spot from Coffeeholic owners Chien Dien and Tang Cao. If you like Vietnamese coffee, this is great. If you don't, get with the times! Now on to more news: Ramie is turning into a steakhouse for one night only Speaking of hot Vietnamese places, Capitol Hill's Ramie is putting on a wagyu-centric steak night on June 26. Called Bò & Béo, it's a collaboration with Preservation Meat Collective, which supplies many of Seattle's top restaurants. The a la carte menu includes cuts like T-bones, strip loins, and a limited quantity of 21-day dry-aged tomahawks, which at $180 are the most expensive thing on the menu. Smaller dishes include beef heart tartare, bo la lot (beef wrapped in betel leaves), and bap xao (sauteed corn). To book tickets (and reserve those limited-quantity cuts) go here. A cognac pairing is also available. A coffee... rave? That's right: MyBallard reports that there's a new pop-up bringing the worlds of house music and coffee together. It's called Garden Club, and it's hosting events on the last Saturday of every month from 9 a.m. to 2 p.m., and maybe at other, yet-to-be-announced times. You can sip specialty coffee while listening to a DJ set — what a way to spend a weekend morning! It's giving, as they say, Gen Z. Follow Garden Club on Instagram for updates and for future events. Dave's Hot Chicken is on a heater Finally, Dave's Hot Chicken fans rejoice: Your fave is being fruitful and multiplying. The Seattle Times reports that the Los Angeles–born, Drake-backed Nashville-style chicken chain is building a new restaurant in Redmond, with others in Tacoma, Puyallup and Federal Way to come in the next several months. Local franchise owner Sana Keshap originally planned to open 10 restaurants in Washington State, the Times writes, but after the success of the Capitol Hill Dave's (the first in the state), she may open up to 15. Fun nugget (pun intended) from the Times story: Keshap likes to make her restaurants 'feel homey' by doing things like offering dates to customers who are breaking their Ramadan fasts. Sign up for our newsletter.
Yahoo
2 days ago
- Yahoo
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus
SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced the appointment of Shawn Rose, M.D. Ph.D., as its next Chief Medical Officer (CMO) and Head of Research and Development (R&D) starting on June 23, 2025. He replaces David R. Shook, M.D., who will be stepping down from the role to pursue other opportunities in the oncology space. Dr. Rose has dedicated his career to immunology translational medicine and advancing new treatment options for autoimmune patients. In various leadership roles, he has brought forward more than a dozen programs from discovery into clinical development, and he has developed multiple pioneering approved medicines such as Sotyktu, Stelara, and Tremfya. 'Dr. Rose joins the Nkarta team at a critical threshold as we discover the power of our NK cell platform to treat autoimmune diseases,' said Paul J. Hastings, CEO of Nkarta. 'He is an enterprise leader with a deep clinical background in rheumatology and immunology that's ideally suited to maximize the potential of our allogeneic NK cell platform. Shawn's proven track record as an expert clinician gives me full confidence that he will hit the ground running on day one and meaningfully advance our work in the clinic.' Dr. Rose most recently served as Chief Development Officer, Immunology, at Vividion Therapeutics, working to expand their portfolio by advancing previously undruggable targets in immunology. He also served as interim CMO and Head of Clinical Development at Magenta Therapeutics, working on cell-based therapeutic approaches for patients with cancer, genetic disorders and immune-mediated inflammatory diseases. Dr. Rose also held multiple clinical and development leadership roles at Annexon Biosciences, Janssen Pharmaceuticals, and Bristol-Myers Squibb. He did his postdoctoral research training and clinical training in Internal Medicine and Rheumatology at the Northwestern University Feinberg School of Medicine. 'I am thrilled to join Nkarta to advance innovative cell therapies for patients,' said Dr. Rose. 'I strongly believe that Nkarta's allogeneic NK cell platform has the potential to be a transformational approach for patients with immune-mediated inflammatory disease. I look forward to working closely with Paul and the broader Nkarta team on developing more treatment options for patients.' During the transition, Dr. Rose will work with Dr. Shook, who will remain on as a consultant through July 11. 'Dave was an early pioneer of NK cell therapy while working under Nkarta's scientific founder, Dario Campana, at St. Jude Children's Research Hospital, and he has tirelessly pursued options that were more convenient for patients with safety utmost in mind,' Hastings said. 'Dave has devoted much of his career to make important contributions to the advancement of natural killer cell therapy, leading our early clinical work in cancer and overseeing key aspects of our strategic shift into a new disease area with agility and flexibility. But Dave is a dedicated oncologist, and he has decided to return to the field he loves. He is a fearless advocate for patients and their well-being and a very good friend who will be missed.' About NKX019NKX019 is an allogeneic, cryopreserved, off-the-shelf immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy adult donors. It is engineered with a humanized CD19-directed chimeric antigen receptor (CAR) for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Nkarta is evaluating NKX019 in multiple autoimmune conditions. About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company's website at Cautionary Note on Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," 'plans,' 'potential,' "projects,' 'would' and "future" or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include, but are not limited to, statements concerning Nkarta's expectations regarding any or all of the following: Nkarta's position, plans, strategies, and timelines for the continued and future clinical development and commercial potential of NKX019 (including the future availability and disclosure of clinical data and other updates from Nkarta's clinical trials). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Nkarta's limited operating history and historical losses; Nkarta's lack of any products approved for sale and its ability to achieve profitability; the risk that the results of preclinical studies and early-stage clinical trials may not be predictive of future results; Nkarta's ability to raise additional funding to complete the development and any commercialization of its product candidates; Nkarta's dependence on the clinical success of NKX019; that Nkarta may be delayed in initiating, enrolling patients in or completing its clinical trials; competition from third parties that are developing products for similar uses; Nkarta's ability to obtain, maintain and protect its intellectual property; Nkarta's dependence on third parties in connection with manufacturing, clinical trials and pre-clinical studies; the complexity of the manufacturing process for CAR NK cell therapies; and the success of Nkarta's recent (and any future) cost containment measures. These and other risks and uncertainties are described more fully in Nkarta's filings with the Securities and Exchange Commission ('SEC'), including the 'Risk Factors' section of Nkarta's Annual Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 14, 2025, and Nkarta's other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Nkarta undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Nkarta Media/Investor Contact:Nadir MahmoodNkarta, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Yahoo
Seeking Clues to Dave & Buster's (PLAY) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Wall Street analysts expect Dave & Buster's (PLAY) to post quarterly earnings of $1.05 per share in its upcoming report, which indicates a year-over-year decline of 6.3%. Revenues are expected to be $569.26 million, down 3.2% from the year-ago quarter. The current level reflects an upward revision of 2.4% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period. Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock. While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights. Bearing this in mind, let's now explore the average estimates of specific Dave & Buster's metrics that are commonly monitored and projected by Wall Street analysts. The combined assessment of analysts suggests that 'Entertainment revenues' will likely reach $374.14 million. The estimate indicates a change of -3% from the prior-year quarter. Analysts forecast 'Food and beverage revenues' to reach $195.08 million. The estimate indicates a change of -3.6% from the prior-year quarter. According to the collective judgment of analysts, 'Stores Count - End of Period' should come in at 234. The estimate compares to the year-ago value of all Key Company Metrics for Dave & Buster's here>>>Over the past month, Dave & Buster's shares have recorded returns of +12.9% versus the Zacks S&P 500 composite's +5.2% change. Based on its Zacks Rank #3 (Hold), PLAY will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Dave & Buster's Entertainment, Inc. (PLAY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data